EVIDENCE FOR THE ROLE OF CR-1 (CD35), IN ADDITION TO CR-2 (CD21), IN FACILITATING INFECTION OF HUMAN T-CELLS WITH OPSONIZED HIV

被引:46
作者
DELIBRIAS, CC
KAZATCHKINE, MD
FISCHER, E
机构
[1] Inserm U 28, Hôpital Broussais, Paris
关键词
D O I
10.1111/j.1365-3083.1993.tb01711.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Complement activation by HIV results in the binding of C3 fragments to the gp160 complex and enhanced infection of C3 receptor-bearing target cells. We have studied complement-mediated enhancement of infection of the human CD4-positive T-cell line HPB-ALL which expresses the CR1 (CD35) and CR2 (CD21) receptors for C3. CRI and CR2 are present on 15% and 40% of normal peripheral blood CD4-positive T lymphocytes respectively. Opsonization of the virus with complement resulted in a 3- to 10-fold enhancement of infection of HPB-ALL cells, as assessed by measuring the release of p24 antigen in culture supernatants throughout the culture period. Blockade of CR2 with cross-linked anti-CR2 monoclonal antibodies decreased infection to the level observed with unopsonized virus. Blocking CRI reduced complement-mediated infection by 50-80%. Experiments using serum deficient in complement factor I demonstrated that CRI mediates the interaction between opsonized virus and T cells in addition to its ability to serve as a cofactor for the cleavage of C3b into smaller fragments that interact with CR2. A requirement for CD4 in complement-mediated enhancement of infection was observed with HIV-1 Bru but not with HIV-I RF. Thus, CR1 and CR2 contribute in an independent and complementary fashion to penetration of opsonized virus into complement receptor-expressing T cells. Involvement of CD4 in infection with opsonized virus depends on the viral strain.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 25 条
  • [1] ANTIBODIES AND COMPLEMENT ENHANCE BINDING AND UPTAKE OF HIV-1 BY HUMAN MONOCYTES
    BAKKER, LJ
    NOTTET, HSLM
    DEVOS, NM
    DEGRAAF, L
    VANSTRIJP, JAG
    VISSER, MR
    VERHOEF, J
    [J]. AIDS, 1992, 6 (01) : 35 - 41
  • [2] COMPLEMENT RECEPTOR TYPE-2 MEDIATES INFECTION OF THE HUMAN CD4-NEGATIVE RAJI B-CELL LINE WITH OPSONIZED HIV
    BOYER, V
    DELIBRIAS, C
    NORAZ, N
    FISCHER, E
    KAZATCHKINE, MD
    DESGRANGES, C
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 36 (06) : 879 - 883
  • [3] COMPLEMENT MEDIATES HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF A HUMAN T-CELL LINE IN A CD4-INDEPENDENT AND ANTIBODY-INDEPENDENT FASHION
    BOYER, V
    DESGRANGES, C
    TRABAUD, MA
    FISCHER, E
    KAZATCHKINE, MD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (05) : 1151 - 1158
  • [4] MOUSE MONOCLONAL-ANTIBODIES TO THE HUMAN C3B RECEPTOR
    COOK, J
    FISCHER, E
    BOUCHEIX, C
    MIRSRAHI, M
    JOUVIN, MH
    WEISS, L
    JACK, RM
    KAZATCHKINE, MD
    [J]. MOLECULAR IMMUNOLOGY, 1985, 22 (05) : 531 - 539
  • [5] COMPLEMENT EVASION STRATEGIES OF MICROORGANISMS
    COOPER, NR
    [J]. IMMUNOLOGY TODAY, 1991, 12 (09): : 327 - 331
  • [6] DELIBRIAS C, 1992, PROGR IMMUNOLOGY, V8, P509
  • [7] DELIBRIAS C, 1991, J IMMUNOL, V146, P768
  • [8] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVATES THE CLASSICAL PATHWAY OF COMPLEMENT BY DIRECT C1-BINDING THROUGH SPECIFIC SITES IN THE TRANSMEMBRANE GLYCOPROTEIN-GP41
    EBENBICHLER, CF
    THIELENS, NM
    VORNHAGEN, R
    MARSCHANG, P
    ARLAUD, GJ
    DIERICH, MP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) : 1417 - 1424
  • [9] FEARON DT, 1977, J IMMUNOL, V119, P1248
  • [10] FISCHER E, 1991, J IMMUNOL, V146, P865